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32 Abstract 
33 Adipokines have emerged as central mediators of insulin sensitivity and metabolism, 
34 in part due to the known association of obesity with metabolic syndrome disorders 
35 such as type 2 diabetes. Recent studies in rodents have identified the novel 
36 adipokine vaspin, as playing a protective role in inflammatory metabolic diseases by 
37 functioning to promote insulin sensitivity during metabolic stress.  However, at 
38 present the skeletal muscle and adipose tissue expression of vaspin in humans is 
39 poorly characterised.  Furthermore, the functional role of vaspin in skeletal muscle 
40 insulin sensitivity has not been studied.  Since skeletal muscle is the major tissue for 
41 insulin-stimulated glucose uptake understanding the functional role of vaspin in 
42 human muscle insulin signalling is critical in determining its role in glucose 
43 homeostasis. The objective of this study was to profile the skeletal muscle and 
44 subcutaneous adipose tissue expression of vaspin in humans of varying adiposity 
45 and to determine the functional role of vaspin in mediating insulin signalling and 
46 glucose uptake in human skeletal muscle.  Our data shows that vaspin is secreted 
47 from both human subcutaneous adipose tissue and skeletal muscle, and is more 
48 highly expressed in obese older individuals compared to lean older individuals.  
49 Furthermore, we demonstrate that vaspin induces activation of the PI3K/AKT axis, 
50 independent of insulin receptor activation, promotes GLUT4 expression and 
51 translocation and sensitises older obese human skeletal muscle to insulin-mediated 
52 glucose uptake. 
53
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54 Introduction
55 The recognition that adipose tissue is an endocrine organ, capable of secreting a 
56 plethora of adipose-secreted cytokines (adipokines) that mediate tissue cross-talk, 
57 has transformed our understanding of metabolism, with implications for the treatment 
58 of metabolic diseases such as type 2 diabetes (Bluher 2014; Bluher and Mantzoros 
59 2015).  It has long been established that the accumulation of abdominal fat (central 
60 adiposity) is associated with insulin resistance (Carey, et al. 1996; Kahn and Flier 
61 2000; Pratley, et al. 1995) and it is now known that in obese individuals the adipose 
62 tissue becomes inflamed, with infiltrated T-lymphocytes (Zeyda, et al. 2011) and 
63 macrophages (Weisberg, et al. 2003; Wentworth, et al. 2010; Zeyda, et al. 2007; 
64 Zeyda and Stulnig 2007) promoting the release of pro-inflammatory and anti-
65 inflammatory adipokines from adipocytes (Tilg and Moschen 2006; Zeyda et al. 
66 2007).  In this regard, several studies have profiled adipokine expression and 
67 secretion in visceral fat tissue (VAT) and recent proteomic analysis of adipose tissue 
68 secretome has identified over 600 adipokines (Lehr, et al. 2012). In addition, 
69 adipokines are also secreted from subcutaneous adipose tissue (SAT) (Blaber, et al. 
70 2012; Pellegrinelli, et al. 2015; Skurk, et al. 2007).  Considering that SAT represents 
71 a large proportion of total adipose tissue (Rosqvist, et al. 2017; Rossi, et al. 2011) 
72 SAT-derived adipokines are likely important contributors to tissue cross talk and 
73 systemic inflammatory burden.  
74 The functional role of the adipokines leptin and adiponectin as mediators of 
75 metabolic health and insulin sensitivity are well described.  However, at present the 
76 functional role of many novel adipokines in regulating human insulin sensitivity and 
77 glucose handling is poorly understood (Nicholson, et al. 2018).  Partly this is 
78 because despite skeletal muscle being the major organ for insulin-stimulated glucose 
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79 uptake (Thiebaud, et al. 1982), the expression and functional role of these 
80 adipokines in human skeletal muscle has not been studied (Nicholson et al. 2018).  
81 Given that age is a risk factor for the onset of type II diabetes (Kalyani, et al. 2017), 
82 understanding the effect of these different adipokines on skeletal muscle insulin 
83 sensitivity, particularly in older individuals, is important in determining the potential to 
84 target them therapeutically.  Of the recently identified novel adipokines, one of the 
85 most interesting is vaspin (SERPINA12), a 47 kDa protein, which was first reported 
86 in the VAT of the genetically obese OLETF rat (Hida, et al. 2000).  Importantly, 
87 several different animal models have recently implicated vaspin as an adipokine that 
88 functions to promote insulin sensitivity during metabolic stress.  In a diabetic mouse 
89 model, administration of recombinant vaspin increased insulin sensitivity and glucose 
90 tolerance, whilst reducing the expression of pro-inflammatory adipokines including 
91 TNF-α and resistin and increasing the expression of adiponectin (Hida et al. 2000). 
92 Similar increases in insulin sensitivity have been reported in both db/db and C57BL6 
93 mice following administration with recombinant vaspin (Heiker, et al. 2013), whilst 
94 transgenic mice overexpressing vaspin display improved glucose tolerance and are 
95 protected from obesity when challenged with a high fat diet (Nakatsuka, et al. 2012).  
96 Currently, very little is known with regards to the expression and secretory profile of 
97 vaspin in humans, or its functional role in human skeletal muscle tissue.   However, 
98 serum concentrations of vaspin have been reported to be associated with insulin 
99 resistance in both non-diabetic and type 2 diabetic patient cohorts (Aust, et al. 2009; 
100 Jian, et al. 2014; Teshigawara, et al. 2012; Youn, et al. 2008), and its expression has 
101 been detected in the SAT of obese but not lean individuals (Kloting, et al. 2006), 
102 supporting the notion that vaspin is a key adipokine in mediating metabolic health 
103 and insulin sensitivity (Jian et al. 2014).  Therefore, the aim of this study was to 
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104 examine the expression of vaspin in human skeletal muscle and subcutaneous 
105 adipose tissue in elderly individuals of varying adiposity, and to determine the 
106 functional effect of recombinant human vaspin on insulin signalling and glucose 
107 uptake in human skeletal muscle tissue.  
108
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109 Materials and methods
110 1. Human samples
111 Gluteus maximus skeletal muscle, subcutaneous adipose tissue (SAT) and blood 
112 samples were obtained from 21 lean (BMI 22.8 ± 0.3, age 71 ± 1.6 yr), and 17 obese 
113 (BMI 34.5 ± 0.9, age 66 ± 2 yr) elderly age-matched individuals undergoing elective 
114 hip-replacement surgery at the Royal Orthopaedic Hospital, Birmingham, UK, and 
115 Russell’s Hall Hospital, Dudley, UK.  Diabetic patients and those taking anti-
116 inflammatory medication within two weeks prior to surgery were excluded from the 
117 study. Skeletal muscle biopsies were also collected from n=7 young lean individuals.  
118 Informed consent was obtained from all patients prior to sample collection and full 
119 ethical approval for the study was obtained from the Research Ethics Committee 
120 (NRES 13/NE/0222) in line with the Declaration of Helsinki. 
121 Sample collection, processing, storage and subsequent experimental procedures 
122 were carried out in compliance with Human Tissue Authority guidelines under the 
123 Human Tissue Act (2004). Serum was obtained from blood samples (5 ml) taken at 
124 the time of surgery by allowing them to clot at room temperature for 20-30 min, 
125 followed by centrifugation at 1620g for 10min.  Patient characteristics are detailed in 
126 Table 1. 
127
128 2. Isolation of primary human myoblasts and their differentiation into 
129 myotubes
130 Skeletal muscle samples (~200 mg) were sliced with a scalpel, placed in 5 ml of 
131 0.05% trypsin-EDTA solution and rotated in an incubator (37°C, 5% CO2) for 15 min. 
132 Trypsin was inactivated by the addition 5 ml of myoblast growth media (Ham’s F10 
133 nutrient mix, supplemented with 20% HyClone™ research grade foetal bovine serum 
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134 and 1% penicillin and streptomycin). The solution was centrifuged for 5 min at 2000g 
135 and the resulting pellet re-suspended in 12 ml of myoblast growth medium before 
136 transfer to an uncoated T75 cell culture flask for 20 min. Finally, the solution was 
137 transferred to a T75 cell culture flask pre-coated with 0.2% gelatine. Myoblast growth 
138 medium was replaced every 48h.
139 For experimentation, myoblasts were grown to confluence (5-7 days) and 
140 differentiation into myotubes was induced by replacing myoblast growth media with 
141 differentiation media [Ham’s F10 nutrient mix (Sigma-Aldrich, Dorset, UK), 
142 supplemented with 6% horse serum (Sigma-Aldrich, Dorset, UK) and 1% penicillin 
143 and streptomycin]. Differentiation media was replaced every second day. All 
144 experiments were conducted on the 8th day of differentiation.  Myotubes were 
145 immunostained (Figure 3A) for desmin as previously described (O'Leary, et al. 
146 2017).
147
148 3. Generation of Adipose and Muscle Conditioned Media
149 SAT or skeletal muscle derived from lean and obese subjects was incubated at 
150 37°C, 5% CO2 in serum free culture media (Ham’s F10 nutrient mix, Sigma-Aldrich, 
151 Dorset, UK) at a ratio of 1g:10ml for up to 24 h. In the case of adipose tissue, larger 
152 samples were divided into segments of ~ 1 g to ensure that the surface area of 
153 adipose tissue exposed to medium remained approximately constant. For 
154 timecourse analysis of secreted vaspin, 50 µl aliquots of conditioned media were 
155 taken hourly for 6 h and then again at 24 h. Supernatants were removed and stored 
156 at -80°C for western blot analysis.
157
158
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159 4.  RNA extraction and gene expression analysis 
160 Snap-frozen skeletal muscle and subcutaneous adipose tissue samples (~100mg) 
161 were first ground into a fine powder using a pestle and mortar under liquid nitrogen. 
162 Powdered tissue was immediately transferred to 1ml of Trizol® reagent (Invitrogen) 
163 and homogenised using a Qiagen Tissue Ruptor (Qiagen, Manchester, UK). Primary 
164 human myotubes were lysed in 1ml of TRIzol® reagent (Life technologies, Paisley, 
165 UK). 
166 RNA was extracted as described in the manufacturer’s protocol. RNA was re-
167 suspended in 30 µl of RNase free water (Life technologies, Paisley, UK) and heated 
168 at 55°C for 10 min. RNA was quantified using a Nanodrop 2000 (Life technologies, 
169 Paisley, UK).  Relative mRNA expression was determined by Quantitative Real-Time 
170 Polymerase Chain (qRT-PCR), performed using PrecisionTM OneStepPLUS qRT-
171 PCR (with SYBR-green) mastermix (Primerdesign, UK), 5 ng total RNA and primers 
172 as described in supplementary Table 1. All reactions were performed using a Biorad 
173 sfx cycler (BioRad).
174
175 5.  Immunoblotting analysis
176 Aliquots of powdered skeletal muscle tissue, subcutaneous adipose tissue and 
177 primary human myotubes were lysed in RIPA buffer (Life technologies, Paisley, UK) 
178 containing Phosphatase Inhibitor Cocktail 3 (1:100, Sigma-Aldrich, Dorset, UK) and 
179 Protease Inhibitor Cocktail (1:100, Sigma-Aldrich, Dorset, UK). After addition of RIPA 
180 buffer, samples were placed on ice for 20 min. Total protein in cell and tissue lysates 
181 was quantified by performing a BCA assay (Life technologies, Paisley, UK) and 
182 protein samples prepared for gel electrophoresis by diluting in loading buffer 
183 consisting of, 2-mercaptoethanol (Sigma-Aldrich, Dorset, UK), 4x Laemmli Sample 
Page 9 of 42
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
184 Buffer and double distilled H20, followed by boiling for 10 min in a heat block. For 
185 adipose and muscle-conditioned media samples, 10 l of conditioned media diluted 
186 in loading buffer was loaded per sample. For cell lysates, 10-15µg of protein was 
187 loaded per sample depending on the particular western blot.
188 Samples were loaded into a 5% stacking gel and separated by performing 12% 
189 SDS-page. Protein was transferred to a methanol-activated PVDF membrane (0.2 
190 μm) using a Trans-Blot Turbo™ system (Bio-Rad, Hertfordshire, UK). Membranes 
191 containing protein samples from tissue and primary human myotubes were blocked 
192 with TBS-T containing 5% BSA. Membranes containing protein samples from serum 
193 and adipose conditioned media were blocked with 5% milk, 2% BSA, 0.5% H2O2.
194 Membranes were immuno-probed overnight at 4°C, with primary antibodies as 
195 described in supplementary Table 2, Followed by incubation for 2h at RT with the 
196 appropriate secondary antibody [HRP-linked anti-rabbit/ anti-mouse IgG secondary 
197 antibody (1:10,000; GE Healthcare, Buckinghamshire, UK)]. Blots were developed 
198 using Amersham ECL Prime (GE Healthcare, Buckinghamshire, UK), and imaged 
199 using a ChemiDoc™ MP System (Bio-Rad, Hertfordshire, UK). Densitometry 
200 analysis of bands was performed using an open-source, public domain software 
201 package (Image J v1.47).
202
203 6. Vaspin ELISA
204 Serum vaspin was measured using a commercially available human vaspin ELISA 
205 kit (AdipoGen Life Sciences), following the manufactures instructions. Serum 
206 samples were diluted 1:4 in ELISA buffer and the plate was read on a BioTek EL808 
207 microtiter plate reader (BioTek, Swindon, UK).
208
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209 7.  MesoScale immunoassays
210 Myotubes were cultured in 96-well plates and stimulated with 10 nM human insulin 
211 (I0908, Sigma-Aldrich, Dorset, UK), 100 ng/ml of recombinant human vaspin (R&D 
212 systems, Minneapolis, USA) or 100 ng/ml recombinant human vaspin immediately 
213 followed by 10 nM insulin. Cells were lysed in 90µl MSD lysis buffer (MesoScale 
214 Discovery, Gaithersburg, Massachusetts) containing Phosphatase Inhibitor Cocktail 
215 3 (1:100 dilution, Sigma-Aldrich, Dorset, UK) and a Protease Inhibitor Cocktail (1:100 
216 dilution, Sigma-Aldrich, Dorset, UK). Insulin receptor, IGF1 receptor and AKT 
217 (thr308) phosphorylation, as a percentage of total protein, was determined using 
218 Mesoscale Discovery phospho and total protein assays, performed according to the 
219 manufacturer’s instructions and detected on the SECTOR Imager 6000 (MesoScale 
220 Discovery, Gaithersburg, Massachusetts).
221  
222 8.  Glucose uptake assays
223 Glucose uptake in primary human myotubes was quantified using either a 
224 radiometric or a fluorometric assay. For the radiometric assay, obese myotubes were 
225 cultured in 6-well plates and either left unstimulated or were pre-incubated for 24 h 
226 with vaspin (100 ng/ml). The next day myotubes were washed twice in warm PBS 
227 and incubated in serum-free media (Ham’s F10) for 2 h. Myotubes were washed a 
228 further 2 times before incubation with 2 ml reaction buffer (138 mM NaCl, 1.85 mM 
229 CaCl2, 1.3 mM MgSO4, 4.8 mM KCl, 50 mM HEPES pH 7.4, 0.2% (W/V) BSA) for 
230 45 min at 37°C. Myotubes were then incubated with or without insulin (100 nM) for 
231 30 min on a plate warmer at 37°C before the addition of 250 µL of 27.8 kBq [3H]-2-
232 DOG and 10 µM 2-DOG at timed intervals to each well for 15 min. The buffer was 
233 aspirated with a vacuum pump and myotubes were washed 3 times with ice cold 
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234 PBS containing 10 mM glucose. Myotubes were then lysed in 500 L 0.5 M NaOH 
235 and 0.1% SDS then transferred to scintillation vials and 5 ml liquid scintillation fluid 
236 was added. Samples were vortexed and assayed for [3H]-2-DOG uptake expressed 
237 as disintegrations/min/well using a -counter.
238 For the fluorometric assay, lean and obese myotubes cultured in 96 well plates were 
239 washed 3 times in PBS before incubation with glucose free DMEM media (Gibco, 
240 Lougborough, UK) for 3 h. Myotubes were washed a further 3 times before 
241 incubation with 100 µM 2-NBDG glucose (Sigma), diluted in glucose free media with 
242 or without 100nM insulin, for 30 min. Myotubes were subject to a further 3 washes 
243 with PBS before final addition of 100µl PBS/well.  Fluorescence was measured by 
244 excitation at 485 nm and emission at 528 nm using a Synergy™ 2 Multi-Detection 
245 Microplate Reader (BioTek, Swindon, UK).  Untreated myotubes were included to 
246 correct for myotube auto-fluorescence. 5 biological replicates were performed per 
247 condition for each cell line.
248
249 9. Quantification of GLUT4 translocation by flow cytometry
250 Quantification of GLUT4 translocation to the cell membrane was determined by flow 
251 cytometry in myoblasts as previously described (Koshy, et al. 2010).  In brief, 
252 primary human myoblasts (105 cells/condition) from obese subjects (n=5) were 
253 treated with either vaspin (100ng/ml, 15min) or insulin (100nM, 15 min). Post-
254 treatment, cells were washed with PBS and stained for GLUT4 (Anti-GLUT4 
255 antibody ab65267, Abcam. 0.05µg/105 cells, diluted in 2% BSA PBS) on ice for 
256 20min. A second wash with PBS was then preformed, before addition of the 
257 secondary antibody (Alexa Flour 488 goat anti-mouse IgG, Invitrogen, Thermofisher 
258 Scientific. 5 µg/ml diluted in 2% BSA PBS) for 20 min on ice. Cells were then washed 
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259 in PBS and fixed with paraformaldehyde (Medium A, Life Technologies) for 20 min at 
260 RT. Following a single wash in PBS cells were re-suspended in PBS and the relative 
261 surface expression of GLUT4 quantified by measuring the mean fluorescence 
262 intensity (MFI) of a minimum 1500 cells/condition using an AccuriC6TM bench top 
263 flow cytometer (BD Biosciences).
264
265 Statistical analysis
266 Data analysis was carried out using Graphpad Prism v5 statistical package.  The 
267 normality of data was established by a Shapiro-Wilk test.  Significance was 
268 determined by parametric t-tests and by ANOVA with Dunnett’s post-hoc tests where 
269 appropriate, and are detailed in the figure legends.  The correlation of vaspin and 
270 GRP78 expression with BMI was assessed by determining the Pearson correlation 
271 coefficient.  Data is presented as mean ± SEM, with a p value of < 0.05 considered 
272 statistically significant. 
273
274
275
276
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277 Results
278 1.  The expression of vaspin and its putative receptor GRP78 are increased in 
279 the skeletal muscle and subcutaneous adipose tissue of obese individuals.
280 We first examined the mRNA expression of vaspin and its putative plasma 
281 membrane receptor GRP78 (HSPA5) in both skeletal muscle and SAT in humans of 
282 varying BMI.  Vaspin mRNA expression  was significantly greater in both SAT (2.5 
283 fold, p<0.01) and skeletal muscle (1.5 fold, p<0.05) of obese subjects in comparison 
284 to lean subjects (Figure 1A, 1B) and demonstrated a significant positive correlation 
285 with BMI (Figure 1E) and skeletal muscle (Figure 1F). Similarly, expression of 
286 GRP78 was significantly greater in both SAT (1.5 fold, p<0.05) and skeletal muscle 
287 (1.8 fold, p<0.05) of obese subjects in comparison to lean subjects (Figure 1C, 1D) 
288 and was positively correlated with BMI in both tissue types (Figure 1G, 1H). 
289
290 2.  Vaspin is rapidly secreted from human adipose tissue and muscle tissue 
291 and is detectable systemically in both lean and obese individuals.
292 To investigate the potential for vaspin to signal between human SAT and skeletal 
293 muscle we first examined by immunoblotting the ex-vivo secretion of vaspin from 
294 SAT and skeletal muscle into culture media over a 24 h time course.  Vaspin was 
295 detected in serum free culture media that had been conditioned with either SAT or 
296 skeletal muscle for 1 h, indicating that vaspin is rapidly secreted from both tissue 
297 types.  The amount of vaspin detected in both SAT and skeletal muscle conditioned 
298 media increased up to 6 h and was maintained for the duration of 24 h (Figure 2A, 
299 2B). Further, a significantly greater level of vaspin was detected in SAT conditioned 
300 media of obese (n=16) in comparison to lean (n=17) at 24 h (Figure 2C). We then 
301 examined by ELISA whether vaspin could be detected systemically in human sera, 
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302 and whether there was a difference in the systemic concentration of vaspin between 
303 lean (n=16) and obese (n=15) individuals.  Vaspin was detected in the serum of both 
304 lean and obese individuals but there was no significant difference between levels 
305 found in obese individuals in comparison to lean individuals in either males or 
306 females (Figure 2D). However, serum vaspin was on average higher in obese 
307 females compared to lean females.  Furthermore, although there was no significant 
308 correlation between between serum vaspin and BMI in males (Figure 2E), in females 
309 we found a significant positive correlation (R2 = 0.267, P<0.05) with BMI (Figure 2F).  
310
311 3.  The effect of vaspin on insulin signalling pathways in primary human 
312 myotubes.
313 We next examined the effect of stimulating primary human myotubes (Figure 3A) 
314 with recombinant human vaspin on insulin signalling pathways.  Firstly, lean primary 
315 myotubes were stimulated with recombinant vaspin (100 ng/ml) acutely for either 5, 
316 10 or 15 min and AKT activity (phosphorylation) quantified using MesoScale 
317 immunoassays (Mesoscale Discovery).  Myotubes stimulated with vaspin for either 
318 10 or 15 min showed a significant 3-fold increase in phosphoAKT (Threonine 
319 308)/total AKT expression (Figure 3B), which along with activation of the other AKT 
320 phosphorylation site (serine 473) was validated by immunoblotting (n=4 patient 
321 replicates) (Figure 3C-E).  To investigate the mechanism of the vaspin-mediated 
322 induction in basal AKT activity we examined whether acute or chronic stimulation of 
323 human myotubes with vaspin led to activation of either the insulin receptor or the IGF 
324 receptor.  As expected, 15 min of insulin stimulation alone induced a significant 
325 increase in the phosphorylation of both the insulin receptor and the IGF receptor 
326 (Figure 3F, 3G). However, stimulation of myotubes with vaspin for either 15 min or 
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327 chronic stimulation for 24 h induced no phosphorylation of either the insulin receptor 
328 or the IGF receptor (Figure 3F, 3G), indicating that vaspin did not directly affect 
329 activation of upstream insulin signalling.  Given these findings, we then examined 
330 whether vaspin affected the activity of downstream insulin signalling by determining 
331 the activity status PI3K by immunoblotting.  Acute stimulation of primary human 
332 myotubes (n=4 patients) with vaspin (100 ng/ml) induced a transient increase in 
333 phosphorylation of PI3K between 10-15 min as determined by immunoblotting 
334 (Figure 3H, 3I).    
335
336 4.  Vaspin induces the expression and translocation of GLUT4 protein and 
337 promotes glucose uptake in the presence of insulin in human myotubes.
338 Following these data, and with the observation that vaspin induced activation of 
339 downstream insulin signalling components, we then investigated the functional 
340 metabolic role of vaspin by examining whether vaspin affected GLUT4 expression 
341 and glucose uptake in primary human myoblasts and myotubes from obese subjects.
342 Firstly, we examined whether there was a difference in skeletal muscle GLUT4 
343 mRNA expression between old obese (n=8), old lean (n=8) and young (n=7) 
344 subjects.  Compared to young subjects, GLUT4 expression was 69% lower in the 
345 skeletal muscles from old obese subjects (p<0.05; Figure 4A).  In line with the 
346 relatively low expression of GLUT4 in old obese muscle, myotubes derived from old 
347 obese subjects also displayed a blunted glucose uptake response to insulin (100 nM, 
348 30 min), in comparison to myotubes cultured from old lean subjects (Figure 4B).
349 Stimulation of obese myotubes with vaspin (100ng/ml) for 24 h induced a significant 
350 (p<0.05) ~5-fold increase in the expression of GLUT4 mRNA (Figure 4C), which 
351 translated into a significant (p<0.05) increase in GLUT4 protein (Figure 4D).    
Page 16 of 42
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
352 Furthermore, stimulation of primary human myoblasts with either insulin (100nM) or 
353 vaspin (100 ng/ml) for 15 min caused a significant (p<0.05) increase in GLUT4 
354 protein surface expression, compared to non-stimulated myoblasts, indicative of an 
355 increase in GLUT4 protein translocation (Figure 4E).
356 We then investigated whether these vaspin-mediated effects on both the expression 
357 and translocation of GLUT4 were sufficient to impact on glucose uptake in previously 
358 insulin-insensitive obese myotubes.  Primary human myotubes from old obese 
359 subjects that had not been pre-treated with vaspin showed no increase in glucose 
360 uptake in response to 30 min of insulin stimulation (100nM), compared to 
361 unstimulated control (Figure 4F).  However, 30 min insulin stimulation significantly 
362 increased glucose uptake in vaspin pre-treated myotubes, compared to control 
363 myotubes (Figure 4F).  Finally, since p38 and AMPK activation have been implicated 
364 in promoting GLUT4 expression we examined the effect of vaspin stimulation on 
365 their activation status.  Acute stimulation of primary human myotubes (0-15 min) with 
366 100ng/ml vaspin induced a significant activation of both p38 (n=4 biological 
367 replicates) and AMPK (n=4 biological replicates), as measured by immunoblotting 
368 (Figure 4G-I).
369
370
371
Page 17 of 42
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
372 Discussion
373 With the current dearth of human data on the adipokine vaspin, this study is the first 
374 to characterise the expression of vaspin in both skeletal muscle and adipose tissue 
375 in elderly individuals of varying BMI and to report the functional effect of vaspin on 
376 human skeletal muscle insulin signalling pathways and glucose uptake.  
377 Previously, vaspin mRNA has been reported to be detectable in only around 15% of 
378 human SAT samples, with no expression reported in SAT of lean subjects (Kloting et 
379 al. 2006). In the present study, we detected vaspin mRNA in both SAT and skeletal 
380 muscle from both lean and obese individuals.  However, vaspin was more highly 
381 expressed in the SAT and skeletal muscles from obese individuals and in both tissue 
382 types its expression positively correlated with BMI.  We also found that vaspin 
383 protein was rapidly secreted from both human SAT and skeletal muscle tissue, with 
384 the quantity secreted from obese tissues being greater than from lean tissues.  
385 Together these data support the findings from rodent studies that describe an 
386 increase in vaspin tissue expression with obesity (Heiker et al. 2013; Hida et al. 
387 2000).  It is important to note that our finding that vaspin expression in adipose and 
388 muscle tissue was increased with obesity was in patients without type II diabetes.  
389 Gene array data in the GEO database does not reveal any significant difference in 
390 vaspin adipose tissue expression between patients with or without insulin resistance 
391 or in those with type II diabetes compared to individuals with normal glucose 
392 tolerance (Edgar, et al. 2002).  Furthermore, a recent report found that circulatory 
393 levels of vaspin in morbidly obese individuals declined following weight loss induced 
394 by laparoscopic sleeve gastrectomy (Ibrahim, et al. 2018).  These findings, together 
395 with our data here, support the notion that vaspin expression in humans is 
396 dependent on BMI irrespective of diabetic status.    
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397 Contrary to previous reports (Youn et al. 2008), we found no significant difference in 
398 serum levels of vaspin in obese individuals compared to lean.  This was despite the 
399 greater expression and secretion of vaspin from obese SAT of these individuals.  
400 This might suggest that elevated secretion of vaspin from SAT in obese individuals is 
401 more likely to have localised effects rather than systemic effects on distal tissues.  
402 However, it should be noted that serum concentrations of vaspin were variable and 
403 therefore with a larger cohort the higher on average concentration of vaspin in obese 
404 individuals may have reached statistical significance.  Furthermore, in females serum 
405 vaspin levels were on average higher in obese compared to lean, and there was a 
406 significant positive correlation with BMI.  Of note, we found no significant correlation 
407 between serum vaspin levels and BMI in males.  It has been previously reported that 
408 systemic concentrations of vaspin are higher in obese females than in obese males 
409 (Esteghamati, et al. 2014; Seeger, et al. 2008; Youn et al. 2008).  These 
410 observations could reflect sex dimorphism in SAT distribution and quantity (Fuente-
411 Martin, et al. 2013; White and Tchoukalova 2014).  It is known for example that 
412 females predominantly accumulate more SAT than males (Kotani, et al. 1994), and 
413 thus vaspin may play a greater role in mediating glucose homeostasis in females 
414 than in males.  Indeed, some studies have previously reported that the prevalence of 
415 metabolic syndrome is higher in females than in males (Beigh and Jain 2012), with 
416 central adiposity being a greater risk factor for metabolic diseases in females 
417 (Holliday, et al. 2011; Li, et al. 2006).   
418 Vaspin-mediated activation of PI3K/AKT has been reported previously in several 
419 other cell types, including pancreatic cells (Liu, et al. 2017), 3T3-L1 preadipocytes 
420 (Liu, et al. 2015) and endothelial progenitor cells (Sun, et al. 2015).  Furthermore, it 
421 was recently reported that vaspin promotes the PI3K/AKT signalling pathway leading 
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422 to increased GLUT4 protein expression in rats fed a high fat diet (Liu, et al. 2018) 
423 and can improve glucose tolerance in mice (Nakatsuka et al. 2012).  Therefore, our 
424 demonstration that vaspin induces activation of PI3K-AKT signalling and increases 
425 insulin sensitivity in obese human myotubes is significant.  These vaspin-induced 
426 effects appear to occur independently of upstream insulin signalling, since vaspin 
427 had no direct effect on either the insulin receptor or IGF-1 receptor phosphorylation 
428 status.  Activation of PI3K/AKT signalling is known to promote GLUT4 translocation 
429 and glucose uptake in skeletal muscle cells (Dugani and Klip 2005), and here we 
430 report that vaspin promotes GLUT4 expression and translocation and facilitates 
431 glucose uptake in human obese myotubes.  Notably, 15 min stimulation of primary 
432 human myoblasts derived from obese subjects with vaspin was able to significantly 
433 increase GLUT4 surface translocation to a similar magnitude to that observed with 
434 insulin stimulation.  This finding may be of clinical significance given that GLUT4 
435 translocation is impaired in T2D patients with insulin insensitivity (Maria, et al. 2015).  
436 Indeed, since our data shows that vaspin induces insulin signalling independent of 
437 activating the insulin receptor this could provide a novel route to therapeutically 
438 improve glucose maintenance in insulin resistant individuals. 
439 Despite being able to promote GLUT4 translocation we found that insulin stimulation 
440 of obese myotubes did not result in glucose uptake. Previous studies in rats have 
441 demonstrated that GLUT4 expression declines with age (dos Santos, et al. 2012) 
442 and obesity (Kahn and Pedersen 1993).  Here we report for the first time in humans 
443 that muscle tissue derived from elderly obese individuals displayed a significantly 
444 lower expression of GLUT4 mRNA in comparison to young lean individuals. The 
445 retention of this phenotype in primary human myotubes from elderly obese subjects 
446 may therefore explain the blunted insulin response observed at baseline. 
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447 Importantly, prolonged 24 h pre-treatment of obese myotubes with vaspin sensitised 
448 them to insulin-mediated glucose uptake.  This sensitisation is likely due to vaspin 
449 increasing the bioavailable intracellular pool of GLUT4.  Previous studies in 3-T3-L1 
450 adipocytes (Liu et al. 2015) and in mice (Hida, et al. 2005) have reported that vaspin 
451 induces GLUT4 expression.  Here, we report for the first time that vaspin significantly 
452 induces GLUT4 mRNA and GLUT4 protein expression in human skeletal muscle. 
453 Importantly, we also demonstrate that vaspin is able to activate both AMPK and p38 
454 signalling in primary human myotubes. AMPK activation has previously been 
455 reported to upregulate GLUT4 expression in primary human myotubes (McGee, et 
456 al. 2008), while p38 is known to regulate transcription factors that control the 
457 expression of GLUT4 (Montessuit, et al. 2004; Niu, et al. 2003).  Activation of these 
458 signalling pathways may therefore be a potential mechanism to explain the vaspin 
459 induced upregulation in GLUT4 mRNA and protein expression observed.
460 However, it should be noted that primary human myotubes in culture elicit relatively 
461 low insulin stimulated glucose uptake (Aas, et al. 2004; Al-Khalili, et al. 2003; 
462 Montell, et al. 2001), compared to skeletal muscle tissue.  This could be due to low 
463 basal expression of GLUT4, which has been attributed to denervation (Chowdhury, 
464 et al. 2005; Jensen, et al. 2009) and the subsequent absence of contraction.  
465 Therefore, in our model system, treatment of myotubes with vaspin may only be 
466 increasing the pool of bioavailable GLUT4 towards physiological levels. Whether 
467 vaspin administration in humans in vivo would have the same effect remains to be 
468 seen. 
469 A cell surface receptor for vaspin has yet to be fully elucidated.  One possible 
470 mechanism is that vaspin signals through GRP78, a protein that has an important 
471 intracellular regulatory role during cellular ER stress (Lee 2005; Matsuo, et al. 2013). 
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472 However, recent evidence shows GRP78 also functions as a cell surface receptor, 
473 with membrane localised GRP78 binding vaspin and in turn promoting AKT and 
474 AMPK signalling in H-4-II-E-C3 cells (Nakatsuka et al. 2012).   Here, we show 
475 GRP78 expression is present in both SAT and skeletal muscle in older individuals. 
476 Expression of GRP78 was found to be significantly greater in both SAT and skeletal 
477 muscle of obese subjects and displayed a positive correlation with BMI in each case. 
478 This is concurrent with the results of Khadir et al, who also found increased GRP78 
479 expression in SAT of obese humans (Khadir, et al. 2016). Chronic ER stress can be 
480 induced by obesity (Yilmaz 2017) and is associated with inflammatory adipose tissue 
481 (Kawasaki, et al. 2012), and this may explain the increased GRP78 expression in 
482 muscle and adipose tissue of obese individuals in our present study. Additionally, ER 
483 stress has been shown to promote re-localisation of GRP78 to the cell membrane, 
484 thus increasing ligand binding capacity (Zhang, et al. 2010). Whether the functional 
485 effects of vaspin we report here in human myotubes are dependent on GRP78 
486 signalling requires further study.
487 In summary, this study shows that vaspin is directly secreted from both human SAT 
488 and skeletal muscle and its expression is increased with increasing adiposity in older 
489 people. Functionally, vaspin induces PI3K/AKT activation, increases both GLUT4 
490 expression and translocation and promotes insulin-stimulated glucose uptake in 
491 primary obese older human myotubes.  This data support a role for vaspin as a 
492 protective adipokine in the development of insulin resistance in elderly obese 
493 individuals. Further studies are needed to identify the mechanism of action of vaspin 
494 as this may provide a novel therapeutic target to improve insulin sensitivity 
495 independent of the insulin receptor.
496
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512 Figure legends
513 Figure 1.  Vaspin and GRP78 mRNA expression are upregulated in 
514 subcutaneous adipose tissue and skeletal muscle in obese elderly individuals.  
515 (A) The mRNA expression of vaspin in SAT of lean (n=21) and obese (n=17) elderly 
516 individuals.  (B) The mRNA expression of vaspin in skeletal muscle of lean (n=4) and 
517 obese (n=4) elderly.  (C) The mRNA expression of GRP78 in SAT of lean (n=8) and 
518 obese (n=9) elderly.  (D) The mRNA expression of GRP78 in skeletal muscle of lean 
519 (n=7) and obese (n=9) elderly.  (E) Correlation of vaspin mRNA expression in SAT 
520 with BMI.  (F) Correlation of vaspin mRNA expression in skeletal muscle with BMI.  
521 (G) Correlation of GRP78 mRNA expression in SAT with BMI.  (H) Correlation of 
522 GRP78 mRNA expression in skeletal muscle with BMI. Expression of mRNA was 
523 quantified by qRT-PCR, and normalised using GAPDH. Data are represented as 
524 mean ± SEM.  * signifies p<0.05, *** signifies p=<0.001, as determined by unpaired t-
525 tests.
526
527 Figure 2. Vaspin is rapidly secreted from human subcutaneous adipose tissue 
528 and systemically is elevated in obese individuals.  
529 Detection of vaspin protein in (A) SAT conditioned media and (B) skeletal muscle 
530 conditioned media in lean and obese subjects over a 24 h time course, as measured 
531 by immunoblotting.  10 µl adipose or skeletal muscle conditioned media was loaded 
532 per sample lane.  Bars represent mean densitometric units ± SEM of immunblots 
533 from n=3 subjects analysis. *=p<0.05, **=p<0.01, ***=p<0.001, signficicantly different 
534 from time=0 media control sample as determined by one-way ANOVA with Dunnett’s 
535 post-hoc tests.  (C) Densitometric analysis of vaspin protein expression in adipose 
536 conditioned media at 24h from lean (n=17) and obese (n=16) subjects as measured 
R2=0.201
p= 0.0475
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537 by immunoblotting.  10 µl of adipose conditioned media was loaded per sample lane.  
538 *=p<0.05, as determined by unpaired t-test. (D) Detection of vaspin protein in the 
539 serum of male (n=8 lean; n=8 obese) and female (n=8 lean; n=7 obese) subjects by 
540 ELISA.  (E) Pearson correlation of serum vaspin with BMI in males. (F) Pearson 
541 correlation of serum vaspin with BMI in females. 
542
543
544 Figure 3. Vaspin activates downstream insulin signalling pathways in primary 
545 human myotubes.  (A) Representative isolated human myoblasts and differentiated 
546 myotubes immunofluorescently stained with desmin and viewed using a 20X 
547 objective.  (B)  Effect of acute stimulation (0, 5, 10, 15 min) of primary human 
548 myotubes with recombinant human vaspin (100ng/ml) on AKTthr308 phosphorylation 
549 measured by mesoscale analysis (n=4 biological replicates, 2 from male and 2 from 
550 female).  (C) Representative immunoblots of AKTser473 and AKTthr308 phosphorylation 
551 in untreated and vaspin (100 ng/ml) stimulated myotubes after 0, 5, 10 and 15 min 
552 stimulation (n=4 primary donors 2 male, 2 female, 15 ug of total protein was loaded 
553 per sample). (D) Densitometric analysis of AKTThr308 western blots normalised to 
554 Total AKT protein (n=4). (E) Densitometric analysis of AKTser473 western blots relative 
555 to Total AKT protein (n=4). (F) Effect of insulin (0-30 nM, 30min) and acute (15 min) 
556 or chronic (24 h) vaspin stimulation (100 ng/ml) on the phosphorylation of insulin 
557 receptor and (G) IGF receptor as measured by mesoscale analysis (n=16 biological 
558 replicates from 8 primary donors, 4 male, 4 female).  (H) Timecourse of acute vaspin 
559 stimulation (100 ng/ml) on the activation of PI3K assessed by immunoblotting (n=4 
560 primary donors1 male, 3 female).  15 ug total protein was loaded per sample) (I). 
561 Densitometric analysis of Phospho-PI3K western blots normalised to total PI3K,  
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562 Data are represented as mean ± SEM. Data was analysed using one-way ANOVA 
563 with Dunnett’s post-hoc tests. * signifies p<0.05, ** Signifies P<0.01, *** signifies 
564 p<0.001. 
565
566 Figure 4. Vaspin induces GLUT4 expression and sensitises insulin-mediated 
567 glucose uptake in primary human myotubes
568 (A) GLUT4 mRNA expression relative to GAPDH in skeletal muscle tissue derived 
569 from lean young (n=7) lean old (n=8) and obese old (n=8) subjects.  *=p<0.05, 
570 significantly different between young and old obese as determined by one way 
571 ANOVA with Dunnett’s post-hoc tests.  (B) Effect of insulin (100 nM, 30 min) on 2-
572 NBDG glucose uptake in primary human myotubes derived from lean (n=4 females) 
573 and obese (n=3 females) subjects. *=p<0.05, significantly different from unstimulated 
574 control as determined by 2-way ANOVA.  (C) GLUT4 mRNA expression in primary 
575 human myotubes from obese subjects stimulated for 24 h with recombinant vaspin 
576 (100 ng/ml) or left untreated (n= 5 primary donors, 2 male, 3 female).  Expression 
577 was determined by qRT-PCR and normalised to GAPDH.  *=p<0.05, significantly 
578 different from unstimulated control, as determined by t-test.  (D)  GLUT4 protein 
579 expression as measured by immunoblotting in primary human myotubes from obese 
580 subjects stimulated for 24 h with vaspin (100 ng/ml) or left untreated (n=6 primary 
581 donors, 2 male, 4 female).  *=p<0.05, significantly different from unstimulated 
582 control, as determined by t-test.  (E) Primary human myoblast membrane localised 
583 GLUT4 expression in response to insulin (100 nM 15 min), or Vaspin (100 ng/ml 15 
584 min), (n=5 obese primary donors, 2 male, 3 female).  Relative surface expression of 
585 GLUT4 was quantified by measuring the mean fluorescence intensity (MFI) in a 
586 minimum of 1500 cells/ condition by flow cytometry. *=p<0.05, significantly different 
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587 from unstimulated control as determined by one way ANOVA with Dunnett’s post-
588 hoc tests. (F) Effect of 24 h exposure of primary obese myotubes (n=3, female 
589 donor) to recombinant vaspin (100 ng/ml) on basal and insulin-stimulated 
590 radiolabelled glucose uptake ([3H]-2-DOG).  *=p<0.05, significantly different from 
591 unstimulated control as determined by one way ANOVA with Dunnett’s post-hoc 
592 tests.  (G) Representative immunoblots for phospho and total p38 (n=4 primary 
593 donors) and phospho AMPK and total AMPK (n=4 primary donors, 1 male, 3 female) 
594 in untreated and vaspin (100 ng/ml) stimulated myotubes after 0, 5, 10 and 15 min 
595 stimulation. 10 ug of total protein was loaded per sample.   (H)  Densitomertic 
596 quantification of phospo-p38 immunoblots relative to total p38 protein.  Bars present 
597 mean densitometric units  ± SEM (n=4).  *=p<0.05, significantly different from 
598 unstimulated control as determined by one way ANOVA. (I) Densitometric 
599 quantification of phospo-AMPK immunoblots relative to total AMPK.  Bars presesent 
600 mean densitometric units ± SEM (n=3). ** =p<0.01, significantly different from 
601 unstimulated control as determined by one way ANOVA. 
602
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Figure 1.  Vaspin and GRP78 mRNA expression are upregulated in subcutaneous adipose tissue and skeletal 
muscle in obese elderly individuals.   
(A) The mRNA expression of vaspin in SAT of lean (n=21) and obese (n=17) elderly individuals.  (B) The 
mRNA expression of vaspin in skeletal muscle of lean (n=4) and obese (n=4) elderly.  (C) The mRNA 
expression of GRP78 in SAT of lean (n=8) and obese (n=9) elderly.  (D) The mRNA expression of GRP78 in 
skeletal muscle of lean (n=7) and obese (n=9) elderly.  (E) Correlation of vaspin mRNA expression in SAT 
with BMI.  (F) Correlation of vaspin mRNA expression in skeletal muscle with BMI.  (G) Correlation of GRP78 
mRNA expression in SAT with BMI.  (H) Correlation of GRP78 mRNA expression in skeletal muscle with BMI. 
Expression of mRNA was quantified by qRT-PCR, and normalised using GAPDH. Data are represented as 
mean ± SEM.  * signifies p<0.05, *** signifies p=<0.001, as determined by unpaired t-tests. 
275x150mm (300 x 300 DPI) 
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Figure 2. Vaspin is rapidly secreted from human subcutaneous adipose tissue and systemically is elevated in 
obese individuals.   
Detection of vaspin protein in (A) SAT conditioned media and (B) skeletal muscle conditioned media in lean 
and obese subjects over a 24 h time course, as measured by immunoblotting.  10 µl adipose or skeletal 
muscle conditioned media was loaded per sample lane.  Bars represent mean densitometric units ± SEM of 
immunblots from n=3 subjects analysis. *=p<0.05, **=p<0.01, ***=p<0.001, signficicantly different from 
time=0 media control sample as determined by one-way ANOVA with Dunnett’s post-hoc tests.  (C) 
Densitometric analysis of vaspin protein expression in adipose conditioned media at 24h from lean (n=17) 
and obese (n=16) subjects as measured by immunoblotting.  10 µl of adipose conditioned media was loaded 
per sample lane.  *=p<0.05, as determined by unpaired t-test. (D) Detection of vaspin protein in the serum 
of male (n=8 lean; n=8 obese) and female (n=8 lean; n=7 obese) subjects by ELISA.  (E) Pearson 
correlation of serum vaspin with BMI in males. (F) Pearson correlation of serum vaspin with BMI in females. 
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Figure 3. Vaspin activates downstream insulin signalling pathways in primary human myotubes.  (A) 
Representative isolated human myoblasts and differentiated myotubes immunofluorescently stained with 
desmin and viewed using a 20X objective.  (B)  Effect of acute stimulation (0, 5, 10, 15 min) of primary 
human myotubes with recombinant human vaspin (100ng/ml) on AKTthr308 phosphorylation measured by 
mesoscale analysis (n=4 biological replicates, 2 from male and 2 from female).  (C) Representative 
immunoblots of AKTser473 and AKTthr308 phosphorylation in untreated and vaspin (100 ng/ml) stimulated 
myotubes after 0, 5, 10 and 15 min stimulation (n=4 primary donors 2 male, 2 female, 15 ug of total 
protein was loaded per sample). (D) Densitometric analysis of AKTThr308 western blots normalised to Total 
AKT protein (n=4). (E) Densitometric analysis of AKTser473 western blots relative to Total AKT protein 
(n=4). (F) Effect of insulin (0-30 nM, 30min) and acute (15 min) or chronic (24 h) vaspin stimulation (100 
ng/ml) on the phosphorylation of insulin receptor and (G) IGF receptor as measured by mesoscale analysis 
(n=16 biological replicates from 8 primary donors, 4 male, 4 female).  (H) Timecourse of acute vaspin 
stimulation (100 ng/ml) on the activation of PI3K assessed by immunoblotting (n=4 primary donors1 male, 
3 female).  15 ug total protein was loaded per sample) (I). Densitometric analysis of Phospho-PI3K western 
blots normalised to total PI3K,  Data are represented as mean ± SEM. Data was analysed using one-way 
ANOVA with Dunnett’s post-hoc tests. * signifies p<0.05, ** Signifies P<0.01, *** signifies p<0.001. 
150x125mm (300 x 300 DPI) 
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Figure 4. Vaspin induces GLUT4 expression and sensitises insulin-mediated glucose uptake in primary 
human myotubes 
(A) GLUT4 mRNA expression relative to GAPDH in skeletal muscle tissue derived from lean young (n=7) lean 
old (n=8) and obese old (n=8) subjects.  *=p<0.05, significantly different between young and old obese as 
determined by one way ANOVA with Dunnett’s post-hoc tests.  (B) Effect of insulin (100 nM, 30 min) on 2-
NBDG glucose uptake in primary human myotubes derived from lean (n=4 females) and obese (n=3 
females) subjects. *=p<0.05, significantly different from unstimulated control as determined by 2-way 
ANOVA.  (C) GLUT4 mRNA expression in primary human myotubes from obese subjects stimulated for 24 h 
with recombinant vaspin (100 ng/ml) or left untreated (n= 5 primary donors, 2 male, 3 female).  Expression 
was determined by qRT-PCR and normalised to GAPDH.  *=p<0.05, significantly different from unstimulated 
control, as determined by t-test.  (D)  GLUT4 protein expression as measured by immunoblotting in primary 
human myotubes from obese subjects stimulated for 24 h with vaspin (100 ng/ml) or left untreated (n=6 
primary donors, 2 male, 4 female).  *=p<0.05, significantly different from unstimulated control, as 
determined by t-test.  (E) Primary human myoblast membrane localised GLUT4 expression in response to 
insulin (100 nM 15 min), or Vaspin (100 ng/ml 15 min), (n=5 obese primary donors, 2 male, 3 female). 
 Relative surface expression of GLUT4 was quantified by measuring the mean fluorescence intensity (MFI) in 
a minimum of 1500 cells/ condition by flow cytometry. *=p<0.05, significantly different from unstimulated 
control as determined by one way ANOVA with Dunnett’s post-hoc tests. (F) Effect of 24 h exposure of 
primary obese myotubes (n=3, female donor) to recombinant vaspin (100 ng/ml) on basal and insulin-
stimulated radiolabelled glucose uptake ([3H]-2-DOG).  *=p<0.05, significantly different from unstimulated 
control as determined by one way ANOVA with Dunnett’s post-hoc tests.  (G) Representative immunoblots 
for phospho and total p38 (n=4 primary donors) and phospho AMPK and total AMPK (n=4 primary donors, 1 
male, 3 female) in untreated and vaspin (100 ng/ml) stimulated myotubes after 0, 5, 10 and 15 min 
stimulation. 10 ug of total protein was loaded per sample.   (H)  Densitomertic quantification of phospo-p38 
immunoblots relative to total p38 protein.  Bars present mean densitometric units  ± SEM (n=4). 
 *=p<0.05, significantly different from unstimulated control as determined by one way ANOVA. (I) 
Densitometric quantification of phospo-AMPK immunoblots relative to total AMPK.  Bars presesent mean 
densitometric units ± SEM (n=3). ** =p<0.01, significantly different from unstimulated control as 
determined by one way ANOVA. 
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Table 1.  Patient characteristics
Lean Obese p-value
n 21 17
Male/female (n) 9/12 10/7
Age 70.6±1.6 65.8±2.1 0.0718
BMI 22.8 ±0.3 34.5±0.9 < 0.0001
Body fat % 23.6± 3.0 38.6±2.1 0.0006
Weight (Kg) 61.5±2.7 99.2±3.3 < 0.0001
Waist circumference (cm) 81.6±2.9 111.0±2.2 < 0.0001
Hip circumference (cm) 95.9±1.9 115.0±2.2 < 0.0001
Waist: Hip 0.85±0.02 0.95±0.02 0.004
%HbA1c 5.4±0.1 5.7±0.07 0.11
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Supplementary Table 1. PCR Primer Sequences
Gene Manufacturer Sequence
Applied Biosystems Forward Primer: 5’-GGG AGC CTT GGC ATG ATG-3’Vaspin
Reverse Primer: 5’-AGC AAA GGC AAG GGC AGA T-3’
GRP78 Applied Biosystems Forward Primer: 5’-GGCCGCACGTGGAATG-3’
Reverse Primer: 5’- TTGAACGGCAAGAACTTGATGT-3’
GAPDH
GLUT4
Primer Design
Primer Design
Proprietary
Proprietary
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Supplementary Table 2:  Antibodies
Protein target Catalogue #
Phospho AMPK CST 2535S
GLUT4 Abcam ab65267
Phospho AKT473 CST 9271
Phospho AKT 308 CST 9275
Total AKT CST 9272
Total AMPK CST 2532
Total PI3K CST 4257
Vaspin Abcam Ab 101391
PI3Kinase CST 42285
Beta actin  Sigma AC40
Phospho p38 CST 9211
p38 MAPK CST #9212
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Supplementary Figure 1 
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Supplementary Figure 2 
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Supplementary Figure 3 
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Supplementary Figure 4 
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